Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on April 5. While COVID-19 vaccine production was a big talking point for the leader of Moderna, he also touched on how mRNA technology can usher us into a longer life span, saying that he tells all of his friends to “not die” in the next ten years.
BlueWillow’s Non-Viral Intranasal Vaccine Enhances Immunity and Broadens Options
Anthrax, Antigens, Biological, Clinical Trials, COVID-19 Vaccines, Herpes, Immunity, Immunogenicity Data, Immunotherapies, Influenza, Intranasal vaccines, Peanut Allergies, R&D, Respiratory Syncytial Virus (RSV) Infection, VaccinesBlueWillow Biologics demonstrated the safety and immunogenicity in humans of the company’s intranasal technology, which CEO Chad Costley said is the only adjuvanted intranasal platform that is not virus-based.
New research out of Harvard University strongly suggests that infection with the Epstein-Barr virus (EBV) is the leading cause of a debilitating disease of the brain and CNS – multiple sclerosis.
Research Roundup: Link Between Herpes Simplex Virus and Neurogenerative Diseases Gets More Support
Alzheimer’s disease, Clinical Trials, COVID-19 booster shots, Dementia, Herpes Simplex Virus, Medical Journals, Molecules, Multiple Sclerosis, Myelin, Nature Communications, Neurogenerative diseases, Peptides, Proteins, R&D, Rice University, The Lancet, University of Houston, University of Illinois at ChicagoResearchers at the University of Illinois at Chicago published what they are calling a “first of its kind study” that found a possible direct link between neurodegenerative diseases and the herpesvirus.
ESMO: Merck and AstraZeneca’s 5-Year Lynparza Data in Ovarian Cancer and More
Advanced Melanoma, Advanced Squamous Carcinoma of the Anal Canal (SCAC), Biomarkers, Blockbusters, Clinical Data, Clinical Trials, Epstein-Barr Virus, European Society for Medical Oncology (ESMO), Lung Cancer, Ovarian Cancer, PD-1/PD-L1 inhibitors, Platinum-Based Chemotherapy, R&D, TherapeuticsAstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
Roche received authorization from the U.S. Food and Drug Administration for the company’s cobas 6800/8800 diagnostic tests for transplant patients.
Research Roundup: Can Flu and Pneumonia Vaccines Prevent Alzheimer’s and More
Alzheimer's Association International Conference, Alzheimer’s disease, Brain Cells, Cells, Clinical Trials, Duke University, Flu Vaccines, Genes, Genetic Database, Genomes, Herpes, Microbiome, Mutations, Pneumonia Vaccines, R&D, Researchers, Scientific studiesA review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.
Research Roundup: Major Breakthrough in HIV Research and More
Australia, China, Coronavirus Disease 2019 (COVID-19), Drug Cocktails, Genes, Genetic Markers, Genomes, Germany, Herpes Simplex Virus, HIV, Immune Cells, Medical Journals, Mount Sinai, Neurodegenerative Diseases, New England Journal of Medicine, Nucleotides, R&D, RNA, San Francisco (UCSF), Science, Scientific studies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), The Netherlands, Thrombosis Research, University of Alabama at Birmingham (UAB), University of Maryland Baltimore County, Walter and Eliza Hall InstituteA review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.
International Team Develops Promising Broad-Spectrum Antiviral Compound
Antivirals, Biotech, Cyclodextrins, Hepatitis, Herpes Simplex Virus, HIV, HIV Virus, Molecules, Mutations, R&D, Respiratory Syncytial Virus (RSV) Infection, Science Advances, University of Geneva (UNIGE), University of Manchester, Viruses, Zika VirusAn international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.
Merix Pharmaceutical Corp. announced the company’s proprietary botanical extract formula VIRACEA was found to be highly active against HSV-1 and HSV-2 in laboratory testing.